Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any hypotrichosis in which the cause of the disease is a mutation in the KRT74 gene.
Features include always present findings: Sparse scalp hair. 5 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Skin | 1 | Abnormal nail morphology |
KRT74 encodes keratin 74 (529 aa). Has a role in hair formation. Specific component of keratin intermediate filaments in the inner root sheath (IRS) of the hair follicle (Probable) Highest expression in Testis (1.7 TPM) and Skin Sun Exposed Lower leg (1.3 TPM).
Hypotrichosis 3 is associated with mutations in the KRT74 gene on chromosome 12.
KRT74 is classified as a druggable target with score 0.0.
Genetic testing for KRT74 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for hypotrichosis 3 has been reported in the published literature.
Phenotype severity distribution: 1 always present feature.
No clinical trials have been registered for hypotrichosis 3.
201 publications have been identified in PubMed for hypotrichosis 3. Kisho has analyzed 145 by research type. Research spans Review / Meta-Analysis (33%), Clinical Trial Publication (27%), and Epidemiology / Natural History (18%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 48 | 33% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 11:53 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Clinical study results
39 |
27% |
Disease patterns and progression | 26 | 18% |
Laboratory research | 20 | 14% |
Patient case studies | 8 | 6% |
New treatment approaches | 2 | 1% |
Other research | 1 | 1% |
Testing and diagnosis research | 1 | 1% |
Wang Z (2026). [PMID: 41501168](https://pubmed.ncbi.nlm.nih.gov/41501168/). *Nat Rev Urol*. [Review / Meta-Analysis]
Tang GT (2026). [PMID: 41066610](https://pubmed.ncbi.nlm.nih.gov/41066610/). *Clin Exp Dermatol*. [Epidemiology / Natural History]
Tsianakas A (2026). [PMID: 41317911](https://pubmed.ncbi.nlm.nih.gov/41317911/). *J Am Acad Dermatol*. [Clinical Trial Publication]
Zhou C (2026). [PMID: 40976531](https://pubmed.ncbi.nlm.nih.gov/40976531/). *J Am Acad Dermatol*. [Clinical Trial Publication]
Zhu Y (2026). [PMID: 40865676](https://pubmed.ncbi.nlm.nih.gov/40865676/). *J Invest Dermatol*. [Basic Science / Preclinical]
Pipitò C (2026). [PMID: 41178404](https://pubmed.ncbi.nlm.nih.gov/41178404/). *Ital J Dermatol Venerol*. [Review / Meta-Analysis]
Hosny Mahmoud R (2026). [PMID: 40444884](https://pubmed.ncbi.nlm.nih.gov/40444884/). *J Investig Med*. [Basic Science / Preclinical]
Hu BD (2026). [PMID: 41740930](https://pubmed.ncbi.nlm.nih.gov/41740930/). *J Allergy Clin Immunol*. [Basic Science / Preclinical]
Kovalskaia VA (2026). [PMID: 41645317](https://pubmed.ncbi.nlm.nih.gov/41645317/). *Orphanet journal of rare diseases*. [Epidemiology / Natural History]
Green L (2026). [PMID: 41780025](https://pubmed.ncbi.nlm.nih.gov/41780025/). *Am J Manag Care*. [Review / Meta-Analysis]